Effects of peripheral benzodiazepine receptor modulating drugs, Ro 5-4864 and PK 11195, on tension induced by K+ and the calcium agonist SDZ 202 791 (S isomer), were studied in rat caudal arteries. A significant reduction of tonic phase tension occurred with 30 nM PK 11195 or 3 IAM Ro 5-4864, but decreases of the initial (first 3 min), phasic contraction were detected only at the highest concentrations of Ro 5-4864 and PK 11195. Protoporphyrin IX, the putative endogenous ligand of the peripheral benzodiazepine receptor, (at 10-100 nM) markedly increased the effectiveness of Ro 5-4864 and PK 11195 in reducing phasic contraction. Intracellular calcium localization and distribution in fura-2 loaded single vascular cells were quantitated using a high sensitivity, two-stage microchannel plate, photon-counting (PMI-VIM) camera. Peripheral benzodiazepines reduced intracellular calcium release from centrally located calcium pools, and this decrease of calcium release was potentiated by protoporphyrin IX. The decrease in intracellular calcium activity, which was more pronounced in the central regions where sarcoplasmic reticular elements are numerous, was probably the major mechanism of these vasodilator properties.
Introduction
The distinction between two different types of benzodiazepine receptors, peripheral-and central-type, has been developing recently (for review see reference 1). The central-type benzodiazepines are often used for their anxiolytic and anticonvulsant properties, demonstrating good correlation between these classical effects of benzodiazepines and binding (2) . Although benzodiazepine binding has also been characterized in various peripheral tissues, e.g., kidney (3), lung (4) , and liver (5) , and associated with the mitochondrial outer membrane (6) functional correlation in these cases is lacking. Peripheral-type benzodiazepines have been shown to modulate slow action potentials in cardiac tissue (7, 8) , and notably changes induced by calcium agonists and antagonists (9) . However, these cardiac Ca2l channel effects occurred at concentrations > 3 4M, suggesting that only a low-affinity binding site of benzodiazepines is coupled to the Ca2" channel (10) . Furthermore, these studies demonstrated that PK 11195, a compound that selectively displaces Ro 5-4864 from its peripheral benzodiazepine binding site, inhibits the effects of both calcium channel agonists and antagonists.
As no peripheral benzodiazepine receptor studies on vascular tissue have been previously reported, we attempted to determine if peripherally acting benzodiazepine receptor modulators have effects on vascular muscle cells, and if they would interfere with the vasoconstrictor properties of calcium agonists. Because the peripheral-type benzodiazepine binding site is purportedly located on the mitochondrial outer membrane (6), we studied the localization and distribution ofintracellular free calcium in addition to vascular contraction. And because porphyrins, as endogenous ligands for the mitochondrial binding site, compete with and displace benzodiazepines (1 1) , interactions between protoporphyrin IX and peripheral benzodiazepines were investigated, and extended to include investigations of guanylate cyclase activity.
Methods
Isometric tension recording. Wistar-Kyoto (WKY) adult rats that had been etherized and then killed by cervical dislocation were used to provide caudal arteries that were sectioned into 2-mm segments. The segments were placed onto stainless steel stirrups in laminar flow muscle chambers and attached to Akers force transducers for the measurement of isometric tension. The chambers were continuously perfused with ionic solution for mammals (ISM)' consisting of (in millimolar):
130, NaCl; 16, NaHCO3; 0.5, NaH2PO4; 4.7, KCl; 1.8, CaCl2; 0.4, MgCl2; 0.4, MgSO4; 13, Hepes (pH 7.62 at 250C); and 5.5, dextrose (final pH 7.3-7.4), which was aerated with a 95% 02/5% CO2 gas mixture and maintained at a constant temperature of 370C. The artery segments were then stretched until a constant resting tension of 600 dyn was attained.
Adrenergic nerve endings were destroyed by an in vitro 6-hydroxydopamine treatment (12) . After 90-120 min, the arteries were contracted to a steady state with three exposures to 300 nM norepineph- WKY rats were prepared as described previously (15, 16) . After the preparation, the vascular muscle cells were resuspended in CV3 medium and diluted to a density of 70,000 cells/ml before plating onto poly-L-lysine-coated glass coverslips. The cells were maintained in a 5% CO2 incubator at 95% humidity and 37°C. At least 2 d after culturing, coverslips were placed in a laminar flow chamber (volume, 300 ,ul) at 37°C (17) and a single, spontaneously contracting cell was observed at a magnification of 750 on a Leitz Diavert microscope.
Localization and distribution of intracellular free calcium in a single, fura-2-loaded vascular cell was determined as described in detail elsewhere (18) . Briefly, the cells were loaded for 5 min with a fura-2 solution consisting of 20 Ml of a stock solution containing I uM fura-2-acetoxymethylester (19) (1 uM) had no effect on resting tension up to the highest concentrations tested in these experiments. In contrast, addition of K+ (30 or 100 mM) either in the presence or absence of the calcium channel agonist, SDZ 202-791 (S), (from 10 nM to 1 MM) caused reliable contractions of caudal arteries. In 100-mM K+ solutions, there was an initial phasic contraction within 20 s of drug arrival, followed by a submaximal tonic contraction, whereas 30 mM K+ caused a contraction without a phasic portion that developed over 2 min and was maintained or increased until return to ISM (Fig. 1) . Effects of these benzodiazepine modulators on phasic (1-3', peak) and tonic (at 10') portions of contractions during continuous perfusion in K+ stimulating solutions were dose-dependent and summarized in Table I observed if the SDZ Ca2+ channel agonist was present in addition to K+. Effects of Ro 5-4864 were less potent, especially on phasic contraction (Fig. 3) . Ro 15-1788 (the central type benzodiazepine drug) and protoporphyrin IX alone were ineffective upon resting tension or contraction induced by K+ or K+ plus calcium agonist (Table I) . However, although protoporphyrin up to 1 uM had no effect on tension, whether resting or stimulated, the combination of 1 MM protoporphyrin IX and Ro 5-4864 reduced both phasic and tonic contraction to -10% of controls (Fig. 3) . Similarly, in the presence of protoporphyrin IX, the same concentrations of PK 11195 were more effective (Fig. 4) . However, the combination of PK 11195 and Ro 5-4864 gave no additional reduction beyond that of either drug alone. We noted that protoporphyrin IX ( MuM) of Ro 5-4864 (Fig. 3) . The most impressive feature of the enhanced vasorelaxant action with protoporphyrin IX was that phasic contraction, which had not been reduced by even higher Ro 5-4864 concentration without protoporphyrin, was reduced even at submaximal concentrations of Ro 5-4864 protoporphyrin (Fig. 3) .
The inhibition of initial and later phases of contraction induced by K+, or K+ with calcium agonist, is characteristic of calcium channel antagonists. We therefore investigated the effects of the benzodiazepine-modulating drugs, The effect of Ro 5-4864 and of protoporphyrin IX on a soluble guanylate cyclase fraction obtained from pig aortic muscle homogenates was investigated to further explore subcellular mechanisms. In the presence of the benzodiazepine (up to 300 ,uM), only very marginal and inconsistent stimulatory effects of the enzyme activity could be detected, in contrast to investigations on guanylate cyclase prepared from pig lung where a consistent stimulation of guanylate cyclase activity by Ro 5-4864 could be observed (unpublished observations). On the other hand, protoporphyrin IX stimulated the soluble guanylate cyclase consistently. Under our assay conditions, the enzyme from pig aorta was stimulated by the heme four to fivefold with an EC50 of 56 nM (not shown). The benzodiazepine displayed no additional stimulatory effect on the guanylate cyclase when tested in the presence of optimal concentrations of protoporphyrin (i.e., 1 ,uM). Interestingly, however, Ro 5-4864 was found to stimulate cGMP production when tested in the presence of protoporphyrin IX at low concentrations (i.e., 4-10 nM) which are just above the threshold for activation (Fig. 6 ). The enzyme activity was then found to be increased by 40-60% even at submicromolar concentrations of Ro 5-4864.
The results of this study demonstrate for the first time that the peripheral-type benzodiazepine-modulating drugs have vasodilator properties. We have also discovered the powerful enhancement of the vasodilation by the endogenous substance, protoporphyrin IX. This vasodilation is most likely due to interaction with a peripheral-type benzodiazepine receptor. Vasodilation by PK 11 195 was observed only at concentrations > 10 nM, which is higher than that needed in receptor binding studies (6, 21) . The higher concentrations for vasodilation may have several causes. Differences in postreceptor mechanisms might be one explanation (although unlikely), and the lower sensitivity of whole organ preparations than single cells or cell fractions might be another (17) . Alternatively and more likely, the binding site in vascular muscle may have a lower affinity, comparable to that of certain other cells (nerve terminals) (22) .
In this study on caudal arteries, both benzodiazepine-modulating drugs not only reduced the phasic contraction induced by K+, but also reversed the additional contraction during the tonic phase with or without calcium agonist. In a study on cardiac muscle, Mestre et al. (7) In this study, we have restricted our investigations to protoporphyrin IX. However, it has been reported that other porphyrins do also bind, although less, to the same ligand as protoporphyrins IX (1 1). Erythrocytes are the major physiological source of protoporphyrin IX, which when it is released is metabolized to the other porphyrins. Although in plasma from blood donors, protoporphyrin IX is present at concentrations < 2.5 nM (23, 24), this idea could be of potential therapeutic importance for the observed vasodilatory effects ofbenzodiazepine modulators, because in some clinical conditions, associated anemias in chronic disorders, liver disease, intoxications, and in patients with hemolysis after heart valve replacement, porphyrins are markedly elevated (23, 25), reaching levels up to 2 gM in patients with erythropoietic protoporphyria (23).
One of the features reported for high-affinity, peripheral benzodiazepine receptors is that porphyrins are its endogenous ligands (11) , and that an opposite action (interference with vasodilation) might be predicted when benzodiazepines were added to porphyrins, such as protoporphyrin IX, used in this study due to its high affinity for the peripheral benzodiazepine receptor. In contrast to this hypothesis, we detected a marked potentiation of the relaxant effects of both Ro 5-4864 and PK 11195 on the sustained phase of contraction by protoporphyrin IX. Furthermore, and most significantly, we discovered that Ro 5-4864 and PK 11195 in conjunction with protoporphyrin IX were able to reduce both phasic and tonic contraction (even though protoporphyrin IX alone had no effect on tension). This A further interesting finding of this study is the activation of the soluble guanylate cyclase by the concerted action of protoporphyrin IX and the peripheral-type benzodiazepine Ro 5-4864. A series of circumstances drew our attention on the soluble guanylate cyclase as a possible molecular target: (a) the enzyme plays notably a key role in the relaxation of smooth muscles; and (b) its activity is known to be regulated by an endogenous heme (27); and to be stimulated by exogenous protoporphyrin IX (28) . In analogy to the mitochondrial benzodiazepine receptor which also interacts with porphyrins (1 1), it is attractive to imagine that the benzodiazepines can directly interact with (and stimulate) porphyrin binding by guanylate cyclase, thus providing a possible molecular mechanism for their vasodilating effect.
In this study, however, micromolar concentrations of protoporphyrin IX, which maximally stimulate the isolated soluble guanylate cyclase fraction, had no vasodilatory action (see Table I ). The lack of effect can be explained by the absence of specific transport mechanisms at the plasma membrane to facilitate the penetration ofthe heme into the cells. Very likely, the intracellular concentration of protoporphyrin IX during the contraction experiments was not sufficient to cause any relevant stimulation ofthe cyclase activity. On the other hand, it is under such conditions of suboptimal heme concentrations that the benzodiazepine Ro 5-4864 can exert its stimulatory activity on the enzyme. Fig. 6 shows that a synergistic stimulation ofthe cGMP production can be obtained by the concerted interplay of (30) .
In conclusion, drugs interacting with peripheral-type benzodiazepine receptors cause a vasodilation, accompanied by a reduction of intracellular Ca2" release or a stimulation of intracellular Ca2" uptake. This newly described action of benzodiazepines is strongly potentiated by protoporphyrins, possibly by amplified mechanisms at the site of action. A possible mechanism of action could be through cGMP-dependent pathways. Furthermore, these putative benzodiazepine-modulating drugs interfered with direct calcium channel stimulation, suggesting the need for more investigation oftheir role as modulators of the calcium channel.
